Τομέας Κλινικοεργαστηριακός

ptional control over hCdt1. Karakaidos P, Taraviras S, Vassiliou LV, Zacharatos P, Kastrinakis NG, Kougiou D,
Kouloukoussa M, Nishitani H, Papavassiliou AG, Lygerou Z, Gorgoulis VG Am J Pathol. 2004 Oct; 165(4):1351-65.
107. Distinct expression patterns of the transcription factor E2F-1 in relation to tumour growth parameters in common human
carcinomas. Zacharatos P, Kotsinas A, Evangelou K, Karakaidos P, Vassiliou LV, Rezaei N, Kyroudi A, Kittas C, Patsouris
E, Papavassiliou AG, Gorgoulis VG J Pathol. 2004 Jul; 203(3):744-53.
108. Estrogen receptor beta (ERbeta) is expressed in brain astrocytic tumors and declines with dedifferentiation of the neoplasm.Batistatou
A, Stefanou D, Goussia A, Arkoumani E, Papavassiliou AG, Agnantis NJ. J Cancer Res Clin Oncol. 2004
Jul; 130(7):405-10.
109. COX-2 inhibition in cancer therapeutics: a field of controversy or a magic bullet? Karamouzis MV, Papavassiliou AG Expert
Opin Investig Drugs. 2004 Apr; 13(4):359-72. Review.
110. Differential expression of retinoic acid receptor beta (RARbeta) and the AP-1 transcription factor in normal, premalignant
and malignant human laryngeal tissues. Karamouzis MV, Sotiropoulou-Bonikou G, Vandoros G, Varakis I, Papavassiliou
AG Eur J Cancer. 2004 Mar; 40(5):761-73.
111. Androgen receptor (AR) expression is an independent unfavorable prognostic factor in gastric cancer. Kominea A, Konstantinopoulos
PA, Kapranos N, Vandoros G, Gkermpesi M, Andricopoulos P, Artelaris S, Savva S, Varakis I, Sotiropoulou-Bonikou
G, Papavassiliou AG J Cancer Res Clin Oncol. 2004 May; 130(5):253-8.
112. Mining microarray data to identify transcription factors expressed in naive resting but not activated T lymphocytes. Argyropoulos
C, Nikiforidis GC, Theodoropoulou M, Adamopoulos P, Boubali S, Georgakopoulos TN, Paliogianni F, Papavassiliou
AG, Mouzaki A. Genes Immun. 2004 Jan; 5(1):16-25.
ÊéÜñçò ÉððïêñÜôçò, Åðßêïõñïò ÊáèçãçôÞò (óýíïëï 20)
1. Regulation of tumor-stromal fibroblast interactions: implications in anticancer therapy. Kiaris H, Trimis G, Papavassiliou
AG Curr Med Chem. 2008; 15(29):3062-7. Review.
2. Essential role of p21/waf1 in the mediation of the anti-proliferative effects of GHRH antagonist JMR-132. Volakaki AA, Lafkas
D, Kassi E, Schally AV, Papavassiliou AG, Kiaris H. J Mol Endocrinol. 2008 Nov; 41(5):389-92.
3. Expression of p21waf1/Cip1 in stromal fibroblasts of primary breast tumors. Trimis G, Chatzistamou I, Politi K, Kiaris H,
Papavassiliou AG Hum Mol Genet. 2008 Nov 15; 17(22):3596-600.
4. Fibroblast independency in tumors: implications in cancer therapy. Tsellou E, Kiaris H. Future Oncol. 2008 Jun; 4(3):427-
32. Review.
5. P53 mutations in stromal fibroblasts sensitize tumors against chemotherapy. Lafkas D, Trimis G, Papavassiliou AG, Kiaris
H. Int J Cancer. 2008 Aug 15; 123(4):967-71.
6. Prognostic value of computer-assisted morphological and morphometrical analysis for detecting the recurrence tendency
of basal cell carcinoma. Cheretis C, Angelidou E, Dietrich F, Politi E, Kiaris H, Koutselini H. Med Sci Monit. 2008 May;
14(5):MT13-19.
7. ERp29, an endoplasmic reticulum secretion factor is involved in the growth of breast tumor xenografts. Mkrtchian S, Baryshev
M, Sargsyan E, Chatzistamou I, Volakaki AA, Chaviaras N, Pafiti A, Triantafyllou A, Kiaris H. Mol CarcinoG 2008
Nov; 47(11):886-92.
8. Expression of growth hormone-releasing hormone receptor splice variant 1 in primary human melanomas. Chatzistamou
I, Volakaki AA, Schally AV, Kiaris H, Kittas C. Regul Pept. 2008 Apr 10; 147(1-3):33-6.
9. Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone-releasing hormone
receptor. Barabutis N, Tsellou E, Schally AV, Kouloheri S, Kalofoutis A, Kiaris H. Proc Natl Acad Sci U S A. 2007 Mar
27; 104(13):5575-9.
10. Expression of ERp29, an endoplasmic reticulum secretion factor in basal-cell carcinoma. Cheretis C, Dietrich F, Chatzistamou
I, Politi K, Angelidou E, Kiaris H, Mkrtchian S, Koutselini H. Am J Dermatopathol. 2006 Oct; 28(5):410-2.
11. Anatomically independent tumors revisited. Kiaris H. Future Oncol. 2006 Aug; 2(4):463-7. Review.
12. Expression of growth hormone-releasing hormone (GHRH) and splice variant of GHRH receptors in normal mouse tissues.
Christodoulou C, Schally AV, Chatzistamou I, Kondi-Pafiti A, Lamnissou K, Kouloheri S, Kalofoutis A, Kiaris H. Regul
Pept. 2006 Sep 11; 136(1-3):105-8.
13. Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in micE Klinakis A, Szabolcs
M, Politi K, Kiaris H, Artavanis-Tsakonas S, Efstratiadis A. Proc Natl Acad Sci U S A. 2006 Jun 13; 103(24):9262-7.
14. GHRH analogs and cancer. Kiaris H. Comb Chem High Throughput Screen. 2006 Mar; 9(3):161. No abstract available.
15. Estrogen receptor alpha gene polymorphism and systemic lupus erythematosus: a possible risk? Kassi E, Vlachoyiannopoulos
PG, Kominakis A, Kiaris H, Moutsopoulos HM, Moutsatsou P. Lupus. 2005; 14(5):391-8.
16. Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis. Kiaris H, Chatzistamou I, Trimis G, Frangou-Plemmenou
M, Pafiti-Kondi A, Kalofoutis A. Cancer Res. 2005 Mar 1; 65(5):1627-30.
17. Extrapituitary effects of the growth hormone-releasing hormonE Kiaris H, Schally AV, Kalofoutis A. Vitam Horm. 2005;
70:1-24. Review.
2108 ¸êèåóç ÅóùôåñéêÞò Áîéïëüãçóçò (Ðñüôõðï ó÷Þìá)